Tag: GlobeNewswire

EDMONTON, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) — SNDL Inc. (NASDAQ: SNDL, CSE: SNDL) (“SNDL” or the “Company”) announced today that Carlo Cannell has resigned from the Board of Directors effective immediately. The Company thanks Mr. Cannell for his contributions.

ABOUT SNDL INC. 

SNDL Inc. (NASDAQ: SNDL, CSE: SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis companies and the largest private-sector liquor and cannabis retailer in Canada, with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf and Cost Cannabis. With products available in licensed cannabis retail locations nationally, SNDL’s consumer-facing cannabis brands include Top Leaf, Contraband, Palmetto, Bon Jak, La Plogue, Versus, Value Buds, Grasslands, Vacay, Pearls by Grön, No Future and Bhang Chocolate. SNDL’s investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the North American cannabis industry. For more information, please visit www.sndl.com 

For more information: 
Tomas Bottger
SNDL Inc. 
O: 1.587.327.2017 
E: investors@sndl.com

   

EDMONTON, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) — SNDL Inc. (NASDAQ: SNDL, CSE: SNDL) (“SNDL” or the “Company”) announced today that Carlo Cannell has resigned from the Board of Directors effective immediately. The Company thanks Mr. Cannell for his contributions.

ABOUT SNDL INC. 

SNDL Inc. (NASDAQ: SNDL, CSE: SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis companies and the largest private-sector liquor and cannabis retailer in Canada, with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf and Cost Cannabis. With products available in licensed cannabis retail locations nationally, SNDL’s consumer-facing cannabis brands include Top Leaf, Contraband, Palmetto, Bon Jak, La Plogue, Versus, Value Buds, Grasslands, Vacay, Pearls by Grön, No Future and Bhang Chocolate. SNDL’s investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the North American cannabis industry. For more information, please visit www.sndl.com 

For more information: 
Tomas Bottger
SNDL Inc. 
O: 1.587.327.2017 
E: investors@sndl.com

   

VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — Patagonia Gold Corp. (“Patagonia” or the “Company”) (TSXV: PGDC) announces corrections to the Cash Cost¹ and All-In Sustaining Cost¹ (“AISC”) figures, the after-tax net present value (“NPV”), internal rate of return (“IRR”), payback period, and the silver recovery assumption disclosed in its news release dated September 28, 2026 announcing the results of the independent Preliminary Economic Assessment (“PEA”) for the Calcatreu Gold-Silver Project (“Calcatreu” or the “Project”) in Río Negro Province, Argentina.

The Cash Cost and AISC figures presented in the September 28, 2026 news release inadvertently included estimated income tax. Income tax is excluded from Cash Cost and AISC under the methodology used by the Company, which is based on World Gold Council’s Guidance Note on Non-GAAP Metrics – All-In Sustaining Costs and All-In Costs. The Company also corrected the calculation of the regional development tax in the PEA model. The previous calculation inadvertently applied the respective gold and silver tax rates to total revenue, rather than applying each rate separately to the corresponding metal’s revenue.

The silver recovery assumption was incorrectly reported in the September 28, 2026 news release as 30% instead of the 45% already used in the PEA economic model. This correction relates solely to the disclosure of that assumption and does not change the modelled silver production, cost metrics or economic results.

The previously reported and revised figures for the PEA are as follows:

PEA Metric	Previously Reported			Revised
After-tax NPV (@10%) (US$ million)	$334			$370
After-tax IRR (%)	282%				315%
After-tax payback period (Years)	0.6				0.5
Silver recovery (%)	30%				45%
Cash Cost1 (US$/oz Au)	$2,139			$1,332
AISC1 (US$/oz Au)	$2,246			$1,439

Figures are rounded. Cash Cost and AISC are projected life-of-mine averages, expressed per ounce of gold and net of silver by-product credits.

The exclusion of estimated income tax from Cash Cost and AISC is a presentation correction and does not affect the underlying after-tax economic analysis. The correction to the regional development tax calculation reduces the projected Cash Cost and AISC, shortens the projected after-tax payback period and increases the projected after-tax NPV and IRR through its effect on the underlying cash flows. Income tax remains included in the after-tax economic analysis.

Together, the exclusion of estimated income tax and the correction to the regional development tax calculation reduce the previously reported Cash Cost by approximately 38% and AISC by approximately 36%. The revised figures in the table above supersede the corresponding figures disclosed in the September 28, 2026 news release.

The PEA outlines an approximately 16-year mine life, a revised after-tax NPV at a 10% discount rate of approximately US$370 million, a revised after-tax IRR of approximately 315%, and a revised after-tax payback period of approximately 0.5 years, based on gold and silver prices of US$3,500/oz and US$35/oz, respectively. The mine life and metal price assumptions remain unchanged.

The economic analysis still indicates that the Project’s NPV is most sensitive to changes in the gold price and comparatively less sensitive to changes in capital costs, operating costs and the discount rate. (See Figure 1 and Table 2 below)

Figure 1: Percent change in NPV with changes in Metal Price, Capex, Opex, and Discount Rate ¹

¹ Base Case (0% change) metal prices per troy ounce were US$3,500 for gold and US$35 for silver.

Table 2: Changes in NPV with changes in Metal Price, Capex, Opex and Discount Rate ²

Variation		Price (US$)		Capex (US$ M)		Opex (US$ M)		Discount Rate
-50	%	$	77	$	401	$	461	$	464
-45	%	$	108	$	398	$	452	$	453
-40	%	$	138	$	395	$	443	$	442
-35	%	$	168	$	392	$	434	$	432
-30	%	$	197	$	389	$	425	$	422
-25	%	$	226	$	386	$	416	$	413
-20	%	$	255	$	383	$	407	$	404
-15	%	$	284	$	380	$	398	$	395
-10	%	$	313	$	377	$	389	$	386
-5	%	$	342	$	374	$	380	$	378
0	%				$		370
5	%	$	399	$	367	$	361	$	363
10	%	$	428	$	364	$	352	$	356
15	%	$	457	$	361	$	343	$	349
20	%	$	486	$	358	$	334	$	342
25	%	$	514	$	355	$	325	$	335
30	%	$	543	$	352	$	316	$	329
35	%	$	572	$	349	$	306	$	323
40	%	$	601	$	346	$	297	$	317
45	%	$	629	$	343	$	287	$	311
50	%	$	658	$	340	$	278	$	306

² Base case metal prices of US$3,500 for gold and US$35 for silver and 10% discount rate.

Christopher van Tienhoven, Chief Executive Officer of the Company, commented:

“We are providing these corrections to ensure that the cost metrics, economic results and silver recovery assumption disclosed for Calcatreu accurately reflect the PEA. The revisions exclude estimated income tax from Cash Cost and AISC and correct the regional development tax calculation, resulting in revised cost metrics, after-tax NPV, IRR and payback figures. The silver recovery correction relates solely to the previously disclosed percentage, as the economic model already used the correct assumption of 45%.”

Technical Report

The technical report being prepared in accordance with National Instrument 43-101 (“NI 43-101”), which was referenced in the September 28, 2026 news release and will be filed on the Company’s SEDAR+ profile within 45 days of such news release, will reflect the revised Cash Cost, AISC, after-tax NPV, after-tax IRR and after-tax payback period disclosed herein, together with the silver recovery assumption of 45% already incorporated in the PEA economic model.

Preliminary Economic Assessment Cautionary Statement

The PEA is preliminary in nature and includes inferred mineral resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves. Mineral resources that are not mineral reserves do not have demonstrated economic viability. There is no certainty that the results of the PEA will be realized. As previously disclosed, the PEA incorporates an updated Mineral Resource Estimate (“MRE”), which contains approximately: 1.50 million tonnes of measured mineral resources grading 3.03 g/t of gold and 23.1 g/t of silver; 5.28 million tonnes of indicated mineral resources grading 2.39 g/t of gold and 23.1 g/t of silver; and 6.44 million tonnes of inferred mineral resources grading 1.54 g/t Au and 15.5 g/t Ag.

Qualified Persons

Donald J. Birak, an independent consulting geologist, Registered Member of SME and Fellow of AusIMM and Carlos Guzmán, Registered Member of the Chilean Mining Commission and Fellow of AusIMM, each a Qualified Person as defined by NI 43-101, have reviewed and approved the scientific and technical information in this news release.

For more information, please contact:

Christopher van Tienhoven
Chief Executive Officer
Patagonia Gold Corp.
T: +54 11 5278 6950
E: cvantienhoven@patagoniagold.com

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements include, but are not limited to, statements regarding the results and conclusions of the PEA, including the projected mine life, after-tax NPV, after-tax IRR and after-tax payback period; the sensitivity analysis and the illustrative sensitivity cases, including the effects of changes in metal prices, capital costs, operating costs and the discount rate; the underlying assumptions relating to metal prices, production, recoveries, operating and capital costs, taxes and other economic parameters; the potential development and economic performance of the Project; the anticipated timing for filing the NI 43-101 technical report and the expectation that the technical report will reflect the revised measures disclosed in this news release; the potential expansion of mineral resources through further exploration; and planned exploration, technical, permitting and development activities.

Forward-looking statements are based on management’s expectations, estimates and assumptions as at the date of this news release, including assumptions regarding the accuracy of the MRE and the geological, metallurgical, engineering, financial and economic assumptions underlying the PEA; metal prices, foreign exchange rates and metallurgical recoveries; mine plans, production schedules and processing rates; capital and operating costs; taxes, royalties and discount rates; the availability of labour, equipment, supplies, infrastructure and financing; the receipt of required permits and approvals; and the timely completion and filing of the technical report.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. These include the preliminary nature of the PEA and its reliance in part on inferred mineral resources; the uncertainty that the results of the PEA will be realized; uncertainties inherent in mineral resource estimates; fluctuations in commodity prices and foreign exchange rates; variations in recoveries, production, capital and operating costs; inflation and cost escalation; financing, permitting, environmental and regulatory risks; construction, development, operational and technical risks; political, legal, fiscal and social risks in Argentina; title, surface-rights and community-relations risks; exploration risks; and the other risks described in the Company’s public disclosure documents filed on SEDAR+.

Although the Company believes that the expectations and assumptions reflected in these forward-looking statements are reasonable, no assurance can be given that they will prove to be correct. Readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statement, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

^{1 Cash Cost and AISC are non-IFRS measures. These measures have no standardized meaning under IFRS and may not be comparable to similar measures used by other issuers. The figures presented are projected life-of-mine averages derived from the PEA economic model and therefore these prospective non-IFRS financial measures may not be reconciled to the nearest comparable measure under IFRS. These measures are expressed per ounce of gold and net of silver by-product credits, excluding estimated income tax. Additional information regarding these measures and their calculation will be included in the technical report being prepared to support the PEA.}

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/de25ec01-b757-4830-8be1-2713ef4e21f3

VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — Patagonia Gold Corp. (“Patagonia” or the “Company”) (TSXV: PGDC) announces corrections to the Cash Cost¹ and All-In Sustaining Cost¹ (“AISC”) figures, the after-tax net present value (“NPV”), internal rate of return (“IRR”), payback period, and the silver recovery assumption disclosed in its news release dated September 28, 2026 announcing the results of the independent Preliminary Economic Assessment (“PEA”) for the Calcatreu Gold-Silver Project (“Calcatreu” or the “Project”) in Río Negro Province, Argentina.

The Cash Cost and AISC figures presented in the September 28, 2026 news release inadvertently included estimated income tax. Income tax is excluded from Cash Cost and AISC under the methodology used by the Company, which is based on World Gold Council’s Guidance Note on Non-GAAP Metrics – All-In Sustaining Costs and All-In Costs. The Company also corrected the calculation of the regional development tax in the PEA model. The previous calculation inadvertently applied the respective gold and silver tax rates to total revenue, rather than applying each rate separately to the corresponding metal’s revenue.

The silver recovery assumption was incorrectly reported in the September 28, 2026 news release as 30% instead of the 45% already used in the PEA economic model. This correction relates solely to the disclosure of that assumption and does not change the modelled silver production, cost metrics or economic results.

The previously reported and revised figures for the PEA are as follows:

PEA Metric	Previously Reported			Revised
After-tax NPV (@10%) (US$ million)	$334			$370
After-tax IRR (%)	282%				315%
After-tax payback period (Years)	0.6				0.5
Silver recovery (%)	30%				45%
Cash Cost1 (US$/oz Au)	$2,139			$1,332
AISC1 (US$/oz Au)	$2,246			$1,439

Figures are rounded. Cash Cost and AISC are projected life-of-mine averages, expressed per ounce of gold and net of silver by-product credits.

The exclusion of estimated income tax from Cash Cost and AISC is a presentation correction and does not affect the underlying after-tax economic analysis. The correction to the regional development tax calculation reduces the projected Cash Cost and AISC, shortens the projected after-tax payback period and increases the projected after-tax NPV and IRR through its effect on the underlying cash flows. Income tax remains included in the after-tax economic analysis.

Together, the exclusion of estimated income tax and the correction to the regional development tax calculation reduce the previously reported Cash Cost by approximately 38% and AISC by approximately 36%. The revised figures in the table above supersede the corresponding figures disclosed in the September 28, 2026 news release.

The PEA outlines an approximately 16-year mine life, a revised after-tax NPV at a 10% discount rate of approximately US$370 million, a revised after-tax IRR of approximately 315%, and a revised after-tax payback period of approximately 0.5 years, based on gold and silver prices of US$3,500/oz and US$35/oz, respectively. The mine life and metal price assumptions remain unchanged.

The economic analysis still indicates that the Project’s NPV is most sensitive to changes in the gold price and comparatively less sensitive to changes in capital costs, operating costs and the discount rate. (See Figure 1 and Table 2 below)

Figure 1: Percent change in NPV with changes in Metal Price, Capex, Opex, and Discount Rate ¹

¹ Base Case (0% change) metal prices per troy ounce were US$3,500 for gold and US$35 for silver.

Table 2: Changes in NPV with changes in Metal Price, Capex, Opex and Discount Rate ²

Variation		Price (US$)		Capex (US$ M)		Opex (US$ M)		Discount Rate
-50	%	$	77	$	401	$	461	$	464
-45	%	$	108	$	398	$	452	$	453
-40	%	$	138	$	395	$	443	$	442
-35	%	$	168	$	392	$	434	$	432
-30	%	$	197	$	389	$	425	$	422
-25	%	$	226	$	386	$	416	$	413
-20	%	$	255	$	383	$	407	$	404
-15	%	$	284	$	380	$	398	$	395
-10	%	$	313	$	377	$	389	$	386
-5	%	$	342	$	374	$	380	$	378
0	%				$		370
5	%	$	399	$	367	$	361	$	363
10	%	$	428	$	364	$	352	$	356
15	%	$	457	$	361	$	343	$	349
20	%	$	486	$	358	$	334	$	342
25	%	$	514	$	355	$	325	$	335
30	%	$	543	$	352	$	316	$	329
35	%	$	572	$	349	$	306	$	323
40	%	$	601	$	346	$	297	$	317
45	%	$	629	$	343	$	287	$	311
50	%	$	658	$	340	$	278	$	306

² Base case metal prices of US$3,500 for gold and US$35 for silver and 10% discount rate.

Christopher van Tienhoven, Chief Executive Officer of the Company, commented:

“We are providing these corrections to ensure that the cost metrics, economic results and silver recovery assumption disclosed for Calcatreu accurately reflect the PEA. The revisions exclude estimated income tax from Cash Cost and AISC and correct the regional development tax calculation, resulting in revised cost metrics, after-tax NPV, IRR and payback figures. The silver recovery correction relates solely to the previously disclosed percentage, as the economic model already used the correct assumption of 45%.”

Technical Report

The technical report being prepared in accordance with National Instrument 43-101 (“NI 43-101”), which was referenced in the September 28, 2026 news release and will be filed on the Company’s SEDAR+ profile within 45 days of such news release, will reflect the revised Cash Cost, AISC, after-tax NPV, after-tax IRR and after-tax payback period disclosed herein, together with the silver recovery assumption of 45% already incorporated in the PEA economic model.

Preliminary Economic Assessment Cautionary Statement

The PEA is preliminary in nature and includes inferred mineral resources that are considered too speculative geologically to have the economic considerations applied to them that would enable them to be categorized as mineral reserves. Mineral resources that are not mineral reserves do not have demonstrated economic viability. There is no certainty that the results of the PEA will be realized. As previously disclosed, the PEA incorporates an updated Mineral Resource Estimate (“MRE”), which contains approximately: 1.50 million tonnes of measured mineral resources grading 3.03 g/t of gold and 23.1 g/t of silver; 5.28 million tonnes of indicated mineral resources grading 2.39 g/t of gold and 23.1 g/t of silver; and 6.44 million tonnes of inferred mineral resources grading 1.54 g/t Au and 15.5 g/t Ag.

Qualified Persons

Donald J. Birak, an independent consulting geologist, Registered Member of SME and Fellow of AusIMM and Carlos Guzmán, Registered Member of the Chilean Mining Commission and Fellow of AusIMM, each a Qualified Person as defined by NI 43-101, have reviewed and approved the scientific and technical information in this news release.

For more information, please contact:

Christopher van Tienhoven
Chief Executive Officer
Patagonia Gold Corp.
T: +54 11 5278 6950
E: cvantienhoven@patagoniagold.com

FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements include, but are not limited to, statements regarding the results and conclusions of the PEA, including the projected mine life, after-tax NPV, after-tax IRR and after-tax payback period; the sensitivity analysis and the illustrative sensitivity cases, including the effects of changes in metal prices, capital costs, operating costs and the discount rate; the underlying assumptions relating to metal prices, production, recoveries, operating and capital costs, taxes and other economic parameters; the potential development and economic performance of the Project; the anticipated timing for filing the NI 43-101 technical report and the expectation that the technical report will reflect the revised measures disclosed in this news release; the potential expansion of mineral resources through further exploration; and planned exploration, technical, permitting and development activities.

Forward-looking statements are based on management’s expectations, estimates and assumptions as at the date of this news release, including assumptions regarding the accuracy of the MRE and the geological, metallurgical, engineering, financial and economic assumptions underlying the PEA; metal prices, foreign exchange rates and metallurgical recoveries; mine plans, production schedules and processing rates; capital and operating costs; taxes, royalties and discount rates; the availability of labour, equipment, supplies, infrastructure and financing; the receipt of required permits and approvals; and the timely completion and filing of the technical report.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied. These include the preliminary nature of the PEA and its reliance in part on inferred mineral resources; the uncertainty that the results of the PEA will be realized; uncertainties inherent in mineral resource estimates; fluctuations in commodity prices and foreign exchange rates; variations in recoveries, production, capital and operating costs; inflation and cost escalation; financing, permitting, environmental and regulatory risks; construction, development, operational and technical risks; political, legal, fiscal and social risks in Argentina; title, surface-rights and community-relations risks; exploration risks; and the other risks described in the Company’s public disclosure documents filed on SEDAR+.

Although the Company believes that the expectations and assumptions reflected in these forward-looking statements are reasonable, no assurance can be given that they will prove to be correct. Readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statement, except as required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

^{1 Cash Cost and AISC are non-IFRS measures. These measures have no standardized meaning under IFRS and may not be comparable to similar measures used by other issuers. The figures presented are projected life-of-mine averages derived from the PEA economic model and therefore these prospective non-IFRS financial measures may not be reconciled to the nearest comparable measure under IFRS. These measures are expressed per ounce of gold and net of silver by-product credits, excluding estimated income tax. Additional information regarding these measures and their calculation will be included in the technical report being prepared to support the PEA.}

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/de25ec01-b757-4830-8be1-2713ef4e21f3

• NEPTUNE is evaluating urcosimod as a potential first-in-class treatment for neuropathic corneal pain
• First patients enrolled by Dr. Melissa Toyos at Toyos Clinic in Nashville, TN

LONDON and NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced first patients enrolled in Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NCP).

“Neuropathic corneal pain is one of the most debilitating conditions I see in my practice, and right now we have no FDA approved therapy to offer these patients, many of whom have tried everything and are still suffering,” said Melissa Toyos, MD. “I believe this trial represents an important step toward determining whether this investigational therapy can address the significant unmet need faced by patients with neuropathic corneal pain.”

Neuropathic corneal pain (NCP) is a chronic, often severe, debilitating condition characterized by severe pain and sensitivity of the eyes, and in some cases the face or head. It is thought to result from damage or dysfunction of the corneal sensory nerves, often in combination with inflammatory processes, and may occur in association with a variety of underlying ocular conditions exhibiting pain that may be disproportionate to observable clinical findings. NCP remains a condition with no FDA-approved treatment options, representing a significant unmet medical need for patients.

“The activation of the first site and initiation of OKYO’s NEPTUNE trial represent an important milestone for building the clinical evidence necessary to support the potential first disease modifying treatment for neuropathic corneal pain (NCP),” said Flavio Mantelli, MD, PhD, Chief Medical Officer of OKYO Pharma. “We are honored to have Dr. Toyos enroll the first patients in the study while activation of other sites expands across leading U.S. medical centers.”

About NEPTUNE Phase 3 Study

The NEPTUNE (Neuropathic Eye Pain Treatment with Urcosimod & Nerve Evaluation) is evaluating urcosimod for neuropathic corneal pain (NCP) clinical trial has initiated in the United States. Patients will be enrolled at multiple clinical sites across the United States and Europe, including Italy, Spain, and France. Patients will receive 4 drops per day for 12 weeks. The primary efficacy endpoint is the change from baseline to end of treatment in ocular pain assessed by VAS score. Additional efficacy endpoints include Quality-of-Life scores and in-vivo confocal microscopy (IVCM) findings. The multicenter trial is designed as a registrational study in accordance with the U.S. Food and Drug Administration (FDA) guidance. For more information on the NEPTUNE study, please visit: NEPTUNE and NCT07838506 on clinicaltrials.gov.

About Urcosimod

OKYO’s lead candidate, urcosimod, is a first-in-class, lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein-coupled-receptor which is typically found on immune cells of the eye responsible for the ocular inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has demonstrated ocular analgesic and anti-inflammatory pharmacologic activity through its dual mechanism of action, supporting its therapeutic potential to address the significant unmet medical need for patients with neuropathic corneal pain.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. For more information, please visit www.okyopharma.com and follow us on LinkedIn.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com

• NEPTUNE is evaluating urcosimod as a potential first-in-class treatment for neuropathic corneal pain
• First patients enrolled by Dr. Melissa Toyos at Toyos Clinic in Nashville, TN

LONDON and NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced first patients enrolled in Phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain (NCP).

“Neuropathic corneal pain is one of the most debilitating conditions I see in my practice, and right now we have no FDA approved therapy to offer these patients, many of whom have tried everything and are still suffering,” said Melissa Toyos, MD. “I believe this trial represents an important step toward determining whether this investigational therapy can address the significant unmet need faced by patients with neuropathic corneal pain.”

Neuropathic corneal pain (NCP) is a chronic, often severe, debilitating condition characterized by severe pain and sensitivity of the eyes, and in some cases the face or head. It is thought to result from damage or dysfunction of the corneal sensory nerves, often in combination with inflammatory processes, and may occur in association with a variety of underlying ocular conditions exhibiting pain that may be disproportionate to observable clinical findings. NCP remains a condition with no FDA-approved treatment options, representing a significant unmet medical need for patients.

“The activation of the first site and initiation of OKYO’s NEPTUNE trial represent an important milestone for building the clinical evidence necessary to support the potential first disease modifying treatment for neuropathic corneal pain (NCP),” said Flavio Mantelli, MD, PhD, Chief Medical Officer of OKYO Pharma. “We are honored to have Dr. Toyos enroll the first patients in the study while activation of other sites expands across leading U.S. medical centers.”

About NEPTUNE Phase 3 Study

The NEPTUNE (Neuropathic Eye Pain Treatment with Urcosimod & Nerve Evaluation) is evaluating urcosimod for neuropathic corneal pain (NCP) clinical trial has initiated in the United States. Patients will be enrolled at multiple clinical sites across the United States and Europe, including Italy, Spain, and France. Patients will receive 4 drops per day for 12 weeks. The primary efficacy endpoint is the change from baseline to end of treatment in ocular pain assessed by VAS score. Additional efficacy endpoints include Quality-of-Life scores and in-vivo confocal microscopy (IVCM) findings. The multicenter trial is designed as a registrational study in accordance with the U.S. Food and Drug Administration (FDA) guidance. For more information on the NEPTUNE study, please visit: NEPTUNE and NCT07838506 on clinicaltrials.gov.

About Urcosimod

OKYO’s lead candidate, urcosimod, is a first-in-class, lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein-coupled-receptor which is typically found on immune cells of the eye responsible for the ocular inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has demonstrated ocular analgesic and anti-inflammatory pharmacologic activity through its dual mechanism of action, supporting its therapeutic potential to address the significant unmet medical need for patients with neuropathic corneal pain.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. For more information, please visit www.okyopharma.com and follow us on LinkedIn.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com

Award honors foundational discoveries in optogenetics and circuit mapping

These discoveries laid the foundation for a new era in neuroscience and helped inspire MapLight’s circuit-based approach to drug discovery

SAN FRANCISCO and BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) — MapLight Therapeutics (Nasdaq: MPLT) celebrates Karl Deisseroth, M.D., Ph.D., co-founder and Scientific Advisory Board member of MapLight, who was awarded the 2026 Nobel Prize in Physiology or Medicine. Dr. Deisseroth shares the honor with Peter Hegemann, Ph.D., of Humboldt University of Berlin, and Georg Nagel, Ph.D., of the University of Würzburg, for their discoveries concerning light-gated ion channels and optogenetics.

The Nobel Assembly recognized optogenetics for transforming scientists’ ability to study how nerve cells shape memories, feelings and behaviors in the living brain, laying the foundation for a new era in neuroscience. Over the past two decades, optogenetics has fundamentally advanced the understanding of the biological basis of behavior, cognition and neuropsychiatric disease.

Dr. Deisseroth’s academic breakthroughs enabled scientists to investigate causal relationships between specific neural circuits and behavior and inspired the founding of MapLight in 2018. MapLight translates insights from circuit neuroscience into a precision approach to drug discovery, using optogenetics and related tools to identify specific cell types and molecular targets linked to psychiatric and neurodevelopmental symptoms. The Company then develops oral small-molecule candidates designed to modulate disease-relevant circuit activity and provide potential therapeutic relief.

This approach underpins the translation of circuit biology into a diverse pipeline of early- and clinical-stage product candidates. The Phase 2 ZEPHYR study of ML-007C-MA, which evolved from optogenetic and other preclinical work at MapLight, recently met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in schizophrenia symptoms. Based on these results, MapLight announced its intention to engage with the FDA in an End-of-Phase 2 (EOP2) meeting and subsequently initiate a Phase 3 study in schizophrenia. Similarly, preclinical work leveraging optogenetics in models of autism informed the design and conduct of the Phase 2 IRIS study. Based on these results, MapLight announced its intention to engage with the FDA in an EOP2 meeting to discuss a planned Phase 3 program in irritability associated with autism.

“Optogenetics began as a way to ask a basic question: how does electrical activity in specific cells give rise to human behavior and emotion?” said Dr. Deisseroth. “Neuroscience has long needed a better understanding of the functional biology of neural circuits and the relationship between circuit dysfunction and disease. I am deeply grateful to the institutions, trainees, and colleagues that have enabled and supported my work over the years, and to Peter Hegemann and Georg Nagel for their foundational contributions. As a practicing psychiatrist, seeing these basic biological discoveries move from the lab into human clinical trials is the ultimate realization of this work.”

“On behalf of everyone at MapLight, congratulations to Karl on this monumental achievement,” said Christopher Kroeger, M.D., Chief Executive Officer of MapLight. “The Nobel recognition of Karl’s academic work is a triumph for basic science and underscores the transformative impact of understanding the brain at the circuit level. Karl’s Nobel work inspired MapLight’s founding premise: that understanding the causal relationship between neural circuits and behavior can enable a more precise approach to developing medicines for complex CNS disorders. We are incredibly proud to celebrate this extraordinary honor with Karl and to continue advancing the mission that his work inspired.”

Additional information about the 2026 Nobel Prize in Physiology or Medicine and the discoveries recognized by the Nobel Assembly is available in its official announcement.

About MapLight Therapeutics

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The Company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The Company’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.

For more information, please visit www.maplightrx.com.

For investor inquiries: investors@maplightrx.com

For media inquiries: media@maplightrx.com

Award honors foundational discoveries in optogenetics and circuit mapping

These discoveries laid the foundation for a new era in neuroscience and helped inspire MapLight’s circuit-based approach to drug discovery

SAN FRANCISCO and BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) — MapLight Therapeutics (Nasdaq: MPLT) celebrates Karl Deisseroth, M.D., Ph.D., co-founder and Scientific Advisory Board member of MapLight, who was awarded the 2026 Nobel Prize in Physiology or Medicine. Dr. Deisseroth shares the honor with Peter Hegemann, Ph.D., of Humboldt University of Berlin, and Georg Nagel, Ph.D., of the University of Würzburg, for their discoveries concerning light-gated ion channels and optogenetics.

The Nobel Assembly recognized optogenetics for transforming scientists’ ability to study how nerve cells shape memories, feelings and behaviors in the living brain, laying the foundation for a new era in neuroscience. Over the past two decades, optogenetics has fundamentally advanced the understanding of the biological basis of behavior, cognition and neuropsychiatric disease.

Dr. Deisseroth’s academic breakthroughs enabled scientists to investigate causal relationships between specific neural circuits and behavior and inspired the founding of MapLight in 2018. MapLight translates insights from circuit neuroscience into a precision approach to drug discovery, using optogenetics and related tools to identify specific cell types and molecular targets linked to psychiatric and neurodevelopmental symptoms. The Company then develops oral small-molecule candidates designed to modulate disease-relevant circuit activity and provide potential therapeutic relief.

This approach underpins the translation of circuit biology into a diverse pipeline of early- and clinical-stage product candidates. The Phase 2 ZEPHYR study of ML-007C-MA, which evolved from optogenetic and other preclinical work at MapLight, recently met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in schizophrenia symptoms. Based on these results, MapLight announced its intention to engage with the FDA in an End-of-Phase 2 (EOP2) meeting and subsequently initiate a Phase 3 study in schizophrenia. Similarly, preclinical work leveraging optogenetics in models of autism informed the design and conduct of the Phase 2 IRIS study. Based on these results, MapLight announced its intention to engage with the FDA in an EOP2 meeting to discuss a planned Phase 3 program in irritability associated with autism.

“Optogenetics began as a way to ask a basic question: how does electrical activity in specific cells give rise to human behavior and emotion?” said Dr. Deisseroth. “Neuroscience has long needed a better understanding of the functional biology of neural circuits and the relationship between circuit dysfunction and disease. I am deeply grateful to the institutions, trainees, and colleagues that have enabled and supported my work over the years, and to Peter Hegemann and Georg Nagel for their foundational contributions. As a practicing psychiatrist, seeing these basic biological discoveries move from the lab into human clinical trials is the ultimate realization of this work.”

“On behalf of everyone at MapLight, congratulations to Karl on this monumental achievement,” said Christopher Kroeger, M.D., Chief Executive Officer of MapLight. “The Nobel recognition of Karl’s academic work is a triumph for basic science and underscores the transformative impact of understanding the brain at the circuit level. Karl’s Nobel work inspired MapLight’s founding premise: that understanding the causal relationship between neural circuits and behavior can enable a more precise approach to developing medicines for complex CNS disorders. We are incredibly proud to celebrate this extraordinary honor with Karl and to continue advancing the mission that his work inspired.”

Additional information about the 2026 Nobel Prize in Physiology or Medicine and the discoveries recognized by the Nobel Assembly is available in its official announcement.

About MapLight Therapeutics

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The Company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The Company’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.

For more information, please visit www.maplightrx.com.

For investor inquiries: investors@maplightrx.com

For media inquiries: media@maplightrx.com

Company Launching Max for All Residential In-Home Trades, a Max Pilot for Commercial and Roofing Customers, Announcing Homh, and Other Key Product Capabilities at Pantheon 2026

ORLANDO, Fla., Oct. 06, 2026 (GLOBE NEWSWIRE) — ServiceTitan (Nasdaq: TTAN), the software platform that powers the trades, is announcing today at Pantheon, ServiceTitan’s annual user conference, that the AI-powered Max package is now available to every residential in-home contractor. The company is also launching a limited Max pilot for commercial and roofing contractors. ServiceTitan also launched the Atlas mobile app, and Homh, its new consumer demand generation platform.

The Max package is the fully loaded version of ServiceTitan’s Agentic Operating System. Its agents draw on context across demand, field, and office to help customers better understand their business, determine what should happen next, and then action, execute and coordinate that work across connected workflows. Rather than optimizing each workflow in isolation, Max can orchestrate nearly the entire business. Over time, Max learns the business to deliver compounding benefits, which have so far resulted in powerful revenue and profitability outcomes for customers.

“The trades are continuing to prove their resilience, while building the physical foundation of the AI revolution at the same time,” said Ara Mahdessian, co-founder and CEO of ServiceTitan. “They deserve to benefit from the technology they’re helping make possible. Bringing Max to every residential in-home contractor gives our customers the ultimate Agentic Operating System to automate complex workflows, adapt in real time, and scale their businesses.”

In addition to expanding access for residential contractors, ServiceTitan is introducing a limited pilot of Max for commercial and roofing contractors. The pilot pairs Atlas and core automations with agents already live in the field, including a site walk and findings write-up copilot, a daily log agent, and an invoice review agent, with an agreement review agent, touchless AP autopilot, a collections agent, and an AFP recommendation advisor expected to come soon.

ServiceTitan is also introducing the Atlas mobile app, a mobile experience that puts a business’s insights and agents directly on an owner’s phone. Owners can ask Atlas about sales performance, revenue or why a number moved and get an answer grounded in the same company-wide data and context running the rest of the business, rather than waiting on a static report.

ServiceTitan is also announcing Homh, its new consumer demand generation platform that makes selected ServiceTitan contractors discoverable and bookable in new channels where consumers or their AI agents are searching. Homh connects homeowners and their AI agents with a network of high-performing ServiceTitan contractors and brings unique ServiceTitan capabilities into the discovery and booking experience, including objective performance signals, real-time availability, and confirmed appointment booking directly into ServiceTitan. Homh is available directly at www.homh.com and works with ChatGPT, Gemini, and Claude, helping participating contractors reach homeowners who are increasingly using AI tools to find and book contractors. As these platforms evolve, ServiceTitan plans to continue working with leading AI providers to make contractors on Homh more discoverable whenever homeowners use AI tools to find and book home services.

ServiceTitan is also expanding its partner ecosystem surrounding the platform, introducing new integrations and capabilities across booking, operations and financing including:

• Adaptive Capacity (AdCap): Gives AI CSRs access to Adaptive Capacity, the intelligence that powers ServiceTitan’s own scheduling, for intelligent booking.
• Ramp partnership: A direct integration into ServiceTitan gives contractors a clear view of job profitability without manual reconciliation.
• Supplier self-service portal: Lets suppliers self-onboard, with several major distributors and manufacturers already live.
• Financing Preapprovals: With Prescreen, built with GreenSky, and QuickScreen — Synchrony’s firm offer of credit, you can identify pre-qualified homeowners up front, making financing part of the conversation from the start.

“AI is changing both how contractors run their businesses and how customers find them,” said Vahe Kuzoyan, co-founder and President of ServiceTitan. “Our job is to turn that progress into lasting value for the trades. That means giving AI agents the context to understand each business, the ability to work alongside its people, and clear rules for when to act and when to ask. ServiceTitan is fiercely committed to helping contractors build more profitable businesses, while delivering exceptional customer service.”

This year’s Pantheon announcements make Max the most advanced way residential contractors can run their businesses, extend that same automation to commercial and exteriors trades, and connect the platform to a growing network of partners, suppliers and AI agents reaching customers.

To learn more about all of the new features and announcements at Pantheon 2026, visit the Pantheon Live Blog.

Pantheon 2026 Keynote Sessions

Pantheon will feature the following keynote presentations from ServiceTitan leaders, and a live webcast of the following keynote sessions will be broadcast here. A replay will be available for 90 days:

October 6, 2026

• 8:30 AM ET – Welcome Keynote with Ara Mahdessian, CEO and Co-Founder of ServiceTitan
• 11:30 AM ET – Run Your Software, Not Your Business: Residential Keynote, led by Abhi Mathur, Chief Technology and Product Officer
• 2:00 PM ET – The New World: Vahe Kuzoyan, Co-Founder and President
• 3:30 PM ET – The Next Era of Commercial: Alex Kablanian, SVP & GM of Commercial and Construction

October 7, 2026

• 10:15 AM ET – The Power of the Ecosystem: ServiceTitan Partners

About ServiceTitan
ServiceTitan is AI for the trades—a purpose-built agentic operating system designed to automate the workflows that run a contracting business, from enterprise commercial construction to residential field service, exteriors and beyond. The company’s end-to-end solution gives contractors the tools they need to run and grow their business, while providing a stellar customer experience. Learn how ServiceTitan is equipping tradespeople with the AI technology they need to keep the world running at: www.servicetitan.com

© 2026 ServiceTitan. All rights reserved. ServiceTitan, the ServiceTitan logo, and all ServiceTitan product and service names mentioned herein are registered trademarks or unregistered trademarks of ServiceTitan, Inc. in the United States and other countries. Other brand names and marks mentioned herein are for identification purposes only and may be the trademarks of their respective holder(s).

Press Contact
Max Wertheimer
ServiceTitan, Inc.
Press@servicetitan.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release may be forward-looking statements. These include statements regarding ServiceTitan’s plans for current or future products, services or features, including the Max package, the Max pilot for commercial and exteriors contractors, the Atlas mobile app, Homh, partner integrations, and other AI and agentic functionality or features; the expected availability, timing and benefits of those products, services and features; plans to extend Homh into consumer large language models and AI advertising platforms; and our market positioning and business or pricing strategy. They also include statements identified by words such as “expects,” “anticipates,” “believes,” “plans,” “intends,” “will,” “coming soon,” and similar expressions. These forward-looking statements are not promises or guarantees of future results. They are based on our current expectations only and are subject to various risks and uncertainties, including those described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as updated in our other filings with the U.S. Securities and Exchange Commission from time to time. Actual results may differ materially from those we anticipate in these statements due to several factors, including those referenced in our filings with the U.S. Securities and Exchange Commission. Products, services or features described in this press release that are not currently generally available, including those described as “coming soon,” may not be delivered on the anticipated timeline or at all. Purchasing decisions should be based on products, services and features that are currently generally available. Forward-looking statements, including those made during the Pantheon 2026 keynote sessions and any replay of them, speak only as of the date they are made, and ServiceTitan undertakes no obligation to update any forward-looking statements, except as required by law.

Company Launching Max for All Residential In-Home Trades, a Max Pilot for Commercial and Roofing Customers, Announcing Homh, and Other Key Product Capabilities at Pantheon 2026

ORLANDO, Fla., Oct. 06, 2026 (GLOBE NEWSWIRE) — ServiceTitan (Nasdaq: TTAN), the software platform that powers the trades, is announcing today at Pantheon, ServiceTitan’s annual user conference, that the AI-powered Max package is now available to every residential in-home contractor. The company is also launching a limited Max pilot for commercial and roofing contractors. ServiceTitan also launched the Atlas mobile app, and Homh, its new consumer demand generation platform.

The Max package is the fully loaded version of ServiceTitan’s Agentic Operating System. Its agents draw on context across demand, field, and office to help customers better understand their business, determine what should happen next, and then action, execute and coordinate that work across connected workflows. Rather than optimizing each workflow in isolation, Max can orchestrate nearly the entire business. Over time, Max learns the business to deliver compounding benefits, which have so far resulted in powerful revenue and profitability outcomes for customers.

“The trades are continuing to prove their resilience, while building the physical foundation of the AI revolution at the same time,” said Ara Mahdessian, co-founder and CEO of ServiceTitan. “They deserve to benefit from the technology they’re helping make possible. Bringing Max to every residential in-home contractor gives our customers the ultimate Agentic Operating System to automate complex workflows, adapt in real time, and scale their businesses.”

In addition to expanding access for residential contractors, ServiceTitan is introducing a limited pilot of Max for commercial and roofing contractors. The pilot pairs Atlas and core automations with agents already live in the field, including a site walk and findings write-up copilot, a daily log agent, and an invoice review agent, with an agreement review agent, touchless AP autopilot, a collections agent, and an AFP recommendation advisor expected to come soon.

ServiceTitan is also introducing the Atlas mobile app, a mobile experience that puts a business’s insights and agents directly on an owner’s phone. Owners can ask Atlas about sales performance, revenue or why a number moved and get an answer grounded in the same company-wide data and context running the rest of the business, rather than waiting on a static report.

ServiceTitan is also announcing Homh, its new consumer demand generation platform that makes selected ServiceTitan contractors discoverable and bookable in new channels where consumers or their AI agents are searching. Homh connects homeowners and their AI agents with a network of high-performing ServiceTitan contractors and brings unique ServiceTitan capabilities into the discovery and booking experience, including objective performance signals, real-time availability, and confirmed appointment booking directly into ServiceTitan. Homh is available directly at www.homh.com and works with ChatGPT, Gemini, and Claude, helping participating contractors reach homeowners who are increasingly using AI tools to find and book contractors. As these platforms evolve, ServiceTitan plans to continue working with leading AI providers to make contractors on Homh more discoverable whenever homeowners use AI tools to find and book home services.

ServiceTitan is also expanding its partner ecosystem surrounding the platform, introducing new integrations and capabilities across booking, operations and financing including:

• Adaptive Capacity (AdCap): Gives AI CSRs access to Adaptive Capacity, the intelligence that powers ServiceTitan’s own scheduling, for intelligent booking.
• Ramp partnership: A direct integration into ServiceTitan gives contractors a clear view of job profitability without manual reconciliation.
• Supplier self-service portal: Lets suppliers self-onboard, with several major distributors and manufacturers already live.
• Financing Preapprovals: With Prescreen, built with GreenSky, and QuickScreen — Synchrony’s firm offer of credit, you can identify pre-qualified homeowners up front, making financing part of the conversation from the start.

“AI is changing both how contractors run their businesses and how customers find them,” said Vahe Kuzoyan, co-founder and President of ServiceTitan. “Our job is to turn that progress into lasting value for the trades. That means giving AI agents the context to understand each business, the ability to work alongside its people, and clear rules for when to act and when to ask. ServiceTitan is fiercely committed to helping contractors build more profitable businesses, while delivering exceptional customer service.”

This year’s Pantheon announcements make Max the most advanced way residential contractors can run their businesses, extend that same automation to commercial and exteriors trades, and connect the platform to a growing network of partners, suppliers and AI agents reaching customers.

To learn more about all of the new features and announcements at Pantheon 2026, visit the Pantheon Live Blog.

Pantheon 2026 Keynote Sessions

Pantheon will feature the following keynote presentations from ServiceTitan leaders, and a live webcast of the following keynote sessions will be broadcast here. A replay will be available for 90 days:

October 6, 2026

• 8:30 AM ET – Welcome Keynote with Ara Mahdessian, CEO and Co-Founder of ServiceTitan
• 11:30 AM ET – Run Your Software, Not Your Business: Residential Keynote, led by Abhi Mathur, Chief Technology and Product Officer
• 2:00 PM ET – The New World: Vahe Kuzoyan, Co-Founder and President
• 3:30 PM ET – The Next Era of Commercial: Alex Kablanian, SVP & GM of Commercial and Construction

October 7, 2026

• 10:15 AM ET – The Power of the Ecosystem: ServiceTitan Partners

About ServiceTitan
ServiceTitan is AI for the trades—a purpose-built agentic operating system designed to automate the workflows that run a contracting business, from enterprise commercial construction to residential field service, exteriors and beyond. The company’s end-to-end solution gives contractors the tools they need to run and grow their business, while providing a stellar customer experience. Learn how ServiceTitan is equipping tradespeople with the AI technology they need to keep the world running at: www.servicetitan.com

© 2026 ServiceTitan. All rights reserved. ServiceTitan, the ServiceTitan logo, and all ServiceTitan product and service names mentioned herein are registered trademarks or unregistered trademarks of ServiceTitan, Inc. in the United States and other countries. Other brand names and marks mentioned herein are for identification purposes only and may be the trademarks of their respective holder(s).

Press Contact
Max Wertheimer
ServiceTitan, Inc.
Press@servicetitan.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release may be forward-looking statements. These include statements regarding ServiceTitan’s plans for current or future products, services or features, including the Max package, the Max pilot for commercial and exteriors contractors, the Atlas mobile app, Homh, partner integrations, and other AI and agentic functionality or features; the expected availability, timing and benefits of those products, services and features; plans to extend Homh into consumer large language models and AI advertising platforms; and our market positioning and business or pricing strategy. They also include statements identified by words such as “expects,” “anticipates,” “believes,” “plans,” “intends,” “will,” “coming soon,” and similar expressions. These forward-looking statements are not promises or guarantees of future results. They are based on our current expectations only and are subject to various risks and uncertainties, including those described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as updated in our other filings with the U.S. Securities and Exchange Commission from time to time. Actual results may differ materially from those we anticipate in these statements due to several factors, including those referenced in our filings with the U.S. Securities and Exchange Commission. Products, services or features described in this press release that are not currently generally available, including those described as “coming soon,” may not be delivered on the anticipated timeline or at all. Purchasing decisions should be based on products, services and features that are currently generally available. Forward-looking statements, including those made during the Pantheon 2026 keynote sessions and any replay of them, speak only as of the date they are made, and ServiceTitan undertakes no obligation to update any forward-looking statements, except as required by law.